In one paragraphArticle in Infection and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Juan Manuel DíazDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.ORCID 0000-0003-4652-4152 Jasmine E J WellsAustralian Infectious Diseases Research Centre and Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia.ORCID 0009-0002-0046-6751 Amanda C MarpleDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.
Blake A ShannonDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.
Aanchal RishiDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.
Irene MartinNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.ORCID 0000-0002-3941-5583 Matthew A CroxenDepartment of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-9564-7952 Gregory J TyrrellDepartment of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-5276-2416 Mark J WalkerAustralian Infectious Diseases Research Centre and Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia.ORCID 0000-0001-7423-2769 Stephan BrouwerAustralian Infectious Diseases Research Centre and Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia.ORCID 0000-0002-9777-2992 John K McCormickDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.ORCID 0000-0003-3742-7289 Funding
CIHR Project Grant 461623Fondation LeducqNational Health and Medical Research Council
6 · The paper itselfAbstract
Multiple countries have observed an alarming increase in scarlet fever cases, and invasive infections often associated with a new sublineage of
Indexed as
Bacterial ProteinsExotoxinsLysogenyProphagesStreptococcal InfectionsStreptococcus PhagesStreptococcus pyogenesAnimalsHumansMembrane ProteinsMiceSuperantigensVirulenceBacterial ProteinsExotoxinsMembrane ProteinsSpeA protein, Streptococcus pyogenesSuperantigensbacteriophagesgroup A Streptococcusinvasive diseaseM1UKscarlet feverStreptococcus pyogenes
Identifiers
PMID41661104
PMCPMC12974143
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390